Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Monday, August 10, 2026

Snapshot: Aug 10, 2026 · 6:00 PM 100 stocks analyzed

Strong Up Day

Mon, Aug 10, 2026 Broad Rally High

Broad market surge led by acquisitions and earnings beats; tech rallies while healthcare stumbles on clinical failures; high dispersion signals opportunity in single-stock selec…

55% Broad rally across all major indices with S&P 500 up 2.01%, NASDAQ +2.67%, and Russell 2000 +1.19%, driven by a wave of M&A announcements (VREX, HZO, BWMN) and strong earnings beats (NESR, POWW, PLBY), while VIX fell 6.3% reflecting eased risk appetite.
30% Healthcare sector dominated the losers list with 32% of declines following catastrophic clinical trial failures: SION crashed 91% on cystic fibrosis drug failure, TENX plunged 89% on pulmonary hypertension trial miss, and HRTX tumbled 32% after patent and guidance risks emerged, offsetting healthcare's 29% share of gainers led by positive Phase 2 data from ABCL and VERU.
15% High dispersion (50 gainers averaging +28%, 50 losers averaging -25%) spawned five debutants including mega-mover WAFU (+76% on AI diversification), signaling a stock-pickers' environment where tactical conviction on individual names outweighed macro momentum.

Healthcare drove 32% of losers 5 names returned after long absences WAFU — first appearance BWMN — first appearance

Market Regime

Mon, Aug 10, 2026 Risk-On conf: medium macro · prototype

+47

Tailwind −100 … +100 · + tailwind / − headwind

VIX15.5 p8 Drawdown-0.1% Held6d · building SinceAug 3

Top drivers: VIX percentile ▲ S&P vs 20d avg ▲ S&P vs 50d avg ▲

processId: history-market-regime

Market Indexes

Mon, Aug 10, 2026 13

S&P 500

7,753.11

+152.61

+2.01%

Dow Jones

53,975.98

+797.57

+1.50%

NASDAQ Composite

26,605.36

+691.46

+2.67%

NASDAQ 100

29,621.81

+845.01

+2.94%

DJ US Total Market

76,781.18

+1,547.97

+2.06%

Russell 1000

4,225.78

+87.36

+2.11%

S&P MidCap 400

3,871.55

+71.13

+1.87%

Russell 2000

3,017.40

+35.49

+1.19%

Russell 2500

1,291.25

−6.75

-0.52%

Russell 3000

4,410.87

+89.55

+2.07%

Nasdaq Financial-100

7,540.76

+21.41

+0.28%

NIFTY 50

24,583.80

−31.10

-0.13%

VIX

15.46

−1.04

-6.30%

Biggest Gainers

Mon, Aug 10, 2026 50

WAFU

Wah Fu Education Group LtdConsumer Defensive

$1.44+$1.04

+76.5%

NASDAQ · Mkt cap $6.3 M

Wah Fu announced expansion into AI vertical large model customization projects, signaling diversification beyond education into industrial AI applications, likely driving the 76% single-day surge as investors repriced the stock on a broader growth narrative.

The August 10 headline announces that Wah Fu has signed and is implementing multi-field AI vertical large model customization projects, explicitly framed as further expanding the company's industrial layout. This represents a material strategic pivot from the company's core business as an online education and exam preparation provider. The announcement establishes new revenue streams and growth optionality in the high-interest AI sector, which typically commands significant valuation multiples. For a smaller-cap stock trading at $1.44 prior to the move, news of entering AI customization markets can trigger strong repricing, especially if the market views the company's education customer base or technical infrastructure as transferable assets. The timing and framing of "multi-field" and "customization" suggests multiple project wins or a platform strategy rather than a single pilot.

BWMN

Bowman Consulting Group Ltd.Industrials

$42.44+$15.24

+56.0%

NASDAQ · Mkt cap $739 M

Bowman Consulting surged 56% on news of a $43-per-share acquisition by Bernhard Capital Partners combined with a Q2 earnings beat and 50% backlog growth, signaling strong operational momentum ahead of the deal close.

The headlines establish that Bowman announced two major catalysts on August 10. First, the company reported Q2 2026 earnings that beat analyst estimates by 31.92% on the bottom line, alongside strong operational metrics including double-digit revenue growth and a 50% year-over-year backlog increase, signaling robust demand. Second and more significantly, the board agreed to a definitive merger with Bernhard Capital Partners at $43 per share, an acquisition price that evidently exceeds the pre-announcement trading level. The combination of an earnings beat, improved forward guidance (reaffirmed for 2026), and a concrete deal at a fixed premium price explains the sharp single-day rally. The stock's ranking as the second-largest gainer on the day reflects the magnitude of these two overlapping positive events.

MTEN

Mingteng International Corporation Inc. Ordinary SharesIndustrials

$1.07+$0.51

+55.2%

VREX

Varex Imaging CorpHealthcare

$18.44+$6.03

+48.6%

NASDAQ · Mkt cap $781 M

Teledyne Technologies announced a $1.1 billion acquisition of Varex Imaging at $18.90 per share in cash on August 10, 2026, representing a 48% premium and explaining the stock's 48.59% same-day surge.

The evidence is unambiguous. Multiple headlines from August 10 confirm that Teledyne Technologies agreed to acquire Varex Imaging for approximately $1.1 billion, or $18.90 per share in cash. The deal announcement occurred around 15:15 UTC and was followed immediately by VREX shares jumping 48%, aligning precisely with the stated acquisition price premium of over 50% relative to Friday's close. The timing of the move, the magnitude of the price target, and the convergence of at least five separate news reports all referencing the same transaction leave no room for ambiguity. A concurrent earnings beat (Q3 delivered +40.91% EPS surprise) and positive sector momentum in healthcare stocks may have provided minor tailwinds, but the acquisition announcement is the dominant driver of the 48.59% daily gain.

PIII

P3 Health Partners Inc.Healthcare

$12.84+$5.54

+47.1%

NASDAQ · Mkt cap $1.8 B

P3 Health Partners announced Q2 2026 results on August 10, 2026, triggering a 47% single-day gain, likely driven by better-than-expected earnings, revenue, or operational metrics that surprised the market positively.

The company released second quarter 2026 financial results on the snapshot date, which coincides exactly with the massive 47% price jump. The headline indicates P3 announced results but does not specify whether earnings beat estimates, whether guidance was raised, or what specific metrics drove the move. For a population health management company, investors typically respond strongly to beats on patient membership growth, medical margin improvement, or revenue acceleration. The gain is substantial enough to suggest a clear positive surprise rather than a modest beat. Without the full earnings release details, we cannot pinpoint whether the driver was profitability, cash flow, patient count, or forward guidance, but the timing makes it nearly certain the announcement caused the move.

HZO

MarineMax IncConsumer Cyclical

$52.11+$16.43

+46.0%

NYSE · Mkt cap $1.2 B

MarineMax surged 46% after announcing a definitive agreement to be acquired by Blackstone Infrastructure Portfolio Company subsidiary Safe Harbor in a $1.5 billion all-cash transaction on August 10, 2026.

The headline evidence is unambiguous. MarineMax announced on August 10 that it has entered into a definitive agreement to be acquired by Safe Harbor Marinas, a Blackstone Infrastructure Portfolio Company, in an all-cash deal valued at $1.5 billion. This is a completed deal announcement, not speculation or rumor. The stock jumped more than 34% by midday and continued climbing to close up 46%, which is typical behavior for a takeover target when the deal is attractive relative to recent trading levels and carries minimal execution risk given it is already definitive. The acquisition of a marina operator and superyacht services company by a major infrastructure-focused buyout firm represents a clean, transformational event that fully accounts for the magnitude of the move.

AUUD

Auddia Inc.Technology

$1.30+$0.40

+45.3%

NASDAQ · Mkt cap $5.5 M

Auddia's SEC effectiveness announcement for its S-4 merger registration statement on August 10 cleared a major regulatory hurdle and positioned the company to set a shareholder vote date, likely catalyzing the 45% single-day rally.

The headline explicitly announces that the SEC declared effective Auddia's S-4 registration statement, which is the formal regulatory approval required before a merger can proceed to shareholder voting. This is a material milestone in any merger process because it removes regulatory uncertainty and signals the transaction is on track to completion. For a small-cap stock trading at $1.30, elimination of a major binary risk and forward visibility on a shareholder meeting typically generates strong short-covering and retail buying interest. The announcement was issued at 11:00 UTC on the snapshot date itself, establishing a clear same-day news catalyst. Auddia describes itself as "AI first" and appears to be merging into a larger entity, which may add growth narrative appeal to retail investors alongside the technical relief from regulatory approval.

RDGT

Ridgetech IncHealthcare

$0.97+$0.30

+41.1%

NASDAQ · Mkt cap $2.9 M

No news headlines appeared in the last 48 hours, so the 41% gain cannot be attributed to a reported event; the move likely reflects technical trading, delayed news pickup, or unconfirmed developments in a micro-cap stock.

The absence of any Yahoo Finance headlines in the past two days means we cannot point to a specific corporate announcement, earnings report, regulatory action, or other named catalyst for this substantial single-day jump. RDGT at $0.97 is a micro-cap security, which are characteristically volatile and prone to outsized moves on minimal volume or on investor sentiment shifts that may not immediately appear in mainstream news feeds. Possible explanations include delayed disclosure of a press release not yet indexed by RSS aggregators, technical momentum from short covering or retail trading activity, unconfirmed rumors circulating on social media or trading forums, or a binary event such as clinical trial results or licensing agreement that has not been formally reported through standard channels. Without corroborating headlines or structural insight into the company, attribution remains speculative.

ALGS

Aligos Therapeutics IncHealthcare

$7.66+$2.04

+36.3%

NASDAQ · Mkt cap $43 M

No news headlines were found in the last 48 hours, so the cause of the 36.30% gain cannot be directly attributed to a named event or announcement. The move likely reflects either a delayed market reaction, technical/short-squeeze activity, or undisclosed company developments.

Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on viral diseases, making it highly sensitive to clinical trial data, regulatory announcements, or partnership news. The complete absence of headlines in the last 48 hours is notable given the magnitude of the gain, which ranks it among the day's nine biggest movers. For biotech companies of this profile, a 36% single-day surge without corresponding public news typically occurs due to one of several mechanisms: anticipation of clinical trial readouts or regulatory decisions announced after market hours or on social media before formal press release, short squeeze activity driven by high short interest, or technical breakout buying. Without access to pre-market announcements, SEC filings, or social media discussions, we cannot definitively identify which mechanism occurred.

ABCL

AbCellera Biologics IncHealthcare

$9.34+$2.40

+34.6%

NASDAQ · Mkt cap $3.7 B

AbCellera announced positive Phase 2 trial results for ABCL635, its hot flash treatment, showing an 83% reduction in vasomotor symptoms with a single dose, driving a 34.58% single-day gain on strong clinical efficacy data.

The stock surge is directly attributable to positive Phase 2 clinical trial results announced on August 10, 2026. AbCellera's drug candidate ABCL635 met both primary endpoints by significantly reducing the frequency and severity of hot flashes compared to placebo, with headline efficacy around 83% symptom reduction after four weeks. The drug is a non-hormonal treatment for moderate-to-severe vasomotor symptoms in menopausal women, addressing an underserved market. The consistent messaging across multiple news sources published within hours of the 11:00 UTC official announcement confirms this is the primary catalyst. Market enthusiasm reflects both the clinical efficacy and favorable tolerability profile, which de-risks the path to Phase 3 and potential commercialization. This represents meaningful proof-of-concept for a condition affecting millions of women globally.

SGLY

Singularity Future Technology Ltd.Industrials

$8.58+$2.00

+32.3%

NASDAQ · Mkt cap $2.7 M

No news headlines were found in the last 48 hours for SGLY, so the 32.26% gain cannot be attributed to a specific disclosed catalyst. The move likely reflects technical trading, retail momentum, or undisclosed information not yet captured in major news feeds.

The absence of any news in the Yahoo Finance RSS feed in the 48 hours preceding this substantial gain makes it difficult to pinpoint a fundamental cause. SGLY, a microcap technology stock, is the type of security that can experience sharp moves on limited volume driven by technical factors, short covering, or social media-driven retail interest. Without confirmed headlines, possible explanations include a delayed earnings report or guidance revision not yet syndicated widely, insider activity building ahead of an announcement, or simply algorithmic or momentum-driven trading in a lightly traded name. The lack of visible news does not rule out a real corporate event; it may simply mean the catalyst has not yet been widely reported or picked up by major financial news aggregators.

STDN

Standard Nuclear, Inc.Basic Materials

$11.45+$2.70

+32.1%

NYSE · Mkt cap $2.4 B

RBC analyst report on 2026-08-10 highlighted Standard Nuclear's strong positioning in the growing TRISO fuel market, likely driving the 32% gain as a near-term catalyst for a nuclear-focused small-cap name.

The only substantive headline tied to STDN is an RBC report issued this morning (2026-08-10 15:40 UTC) noting the company is well positioned in tristructural isotropic fuel, a next-generation nuclear fuel form used in advanced reactors. The timing aligns closely with the intraday surge. The second headline mentioning Apple and HPE is unrelated to STDN. A 32% single-day jump on a favorable analyst positioning note is substantial but not unusual for smaller nuclear or clean energy plays in a rising sector, where sentiment shifts and institutional attention can trigger outsized moves. Without details on the full RBC report (target price, rating change, or any deal/contract announcement), this appears to be analyst validation of existing thesis rather than news of a specific contract or business development.

CJMB

Callan JMB Inc. Common StockIndustrials

$2.00+$0.46

+29.4%

NASDAQ · Mkt cap $15 M

No news headlines were found in the last 48 hours to explain CJMB's 29.45% gain, so the cause remains unclear without additional reporting or company disclosures.

CJMB jumped nearly 30% on August 10, 2026, but no financial news, earnings reports, regulatory filings, or company announcements appear in the available headlines from the prior 48 hours. This disconnect suggests the catalyst either arrived through a channel not captured by Yahoo Finance RSS (such as a direct press release, SEC filing, or after-hours announcement), or the move was driven by technical factors, short covering, or market rumors. Microcap and small-cap stocks like CJMB can exhibit outsized moves on limited volume and modest catalysts. Without confirmed news, reasonable hypotheses include a delayed earnings surprise, a restructuring announcement, or sector-level momentum, but these remain educated guesses rather than grounded conclusions.

GITS

Hanryu Holdings, Inc.Communication Services

$2.74+$0.60

+28.0%

NASDAQ · Mkt cap $6.2 M

No news was found in the last 48 hours, so the 28% gain likely stems from technical factors, rumors, or a delayed announcement not yet indexed in the available headlines.

Yahoo Finance returned no headlines for Hanryu Holdings in the past two days, which makes it impossible to attribute the sharp 28% move to any specific corporate event such as earnings, guidance, M&A activity, or regulatory approval. Given that GITS is a micro-cap trading on NASDAQ (price around $2.74), it is the type of security prone to outsized intraday volatility driven by momentum trading, short covering, social media discussion, or rumors that may not have surfaced in mainstream financial news yet. It is also possible that a material announcement was made but has not yet been picked up by Yahoo Finance's news feed, or that the move reflects delayed market reaction to news from earlier in the week. Without headline evidence, any specific cause remains speculative.

MGIH

Millennium Group International Holdings Limited - Ordinary SharesConsumer Cyclical

$1.72+$0.43

+27.9%

NASDAQ · Mkt cap $17 M

No news headlines were found in the last 48 hours, so the 27.88% gain cannot be directly attributed to a reported corporate event or market-moving announcement for MGIH.

The absence of recent news makes it difficult to pinpoint a specific catalyst for MGIH's strong 27.88% single-day gain. Stocks trading at low price points, especially those under $2, can be particularly sensitive to technical factors such as short covering, algorithmic accumulation, or retail trading interest that may not immediately surface in major news outlets. Alternatively, the move could reflect delayed market reaction to an announcement made before the 48-hour news window, internal company developments not yet publicly disclosed, or sector-wide momentum in the market segment where MGIH operates. Without access to earnings reports, guidance updates, regulatory filings, or other material events, attributing the move to a specific fundamental cause remains speculative.

DDC

DDC Enterprise LimitedConsumer Defensive

$0.55+$0.12

+27.4%

NYSE · Mkt cap $27 M

No news headlines were found in the last 48 hours, so the 27% gain on DDC likely reflects technical buying, a delayed market reaction to an earlier announcement, or sector-specific momentum rather than fresh company-specific catalysts.

The absence of recent news headlines makes it impossible to pinpoint a specific corporate event driving the jump. DDC Enterprise Limited, trading at $0.55 after a substantial single-day gain, could be responding to several factors. Micro-cap and penny stocks often exhibit outsized daily moves on low volume and limited public information, making them sensitive to technical breakouts, short covering, or retail momentum. Alternatively, the move could reflect a delayed market reaction to news that broke outside the 48-hour window, an earnings release, or a positive development announced through channels not captured in the RSS feed sampled. Without confirmed catalysts in the headlines provided, any explanation remains speculative rather than grounded in disclosed facts.

FCUV

Focus Universal, Inc.Technology

$6.41+$1.37

+27.1%

NASDAQ · Mkt cap $5.7 M

No news headlines were found in the last 48 hours to explain the 27% gain, so the catalyst remains unknown. The move may reflect delayed news dissemination, technical trading, or undisclosed company developments.

Yahoo Finance returned zero headlines for Focus Universal in the last 48 hours despite a significant +27% single-day move that ranked it 17 among NASDAQ gainers. This disconnect between substantial price action and absence of reported news creates genuine uncertainty about the underlying cause. For a micro-cap or thinly-traded stock like FCUV, plausible explanations include: first, a material announcement or earnings result that has not yet propagated through major financial news aggregators, creating a lag; second, short-squeeze or technical momentum trading in a low-liquidity name where retail or algorithmic buying can move price sharply; third, insider activity or social-media-driven interest that precedes formal news coverage. Without access to press releases, regulatory filings, or real-time trading data, pinpointing the specific catalyst is not possible from the evidence at hand.

Babcock & Wilcox Enterprises IncIndustrials

$8.91+$2.58

+27.0%

NYSE · Mkt cap $1.1 B

No news headlines were found in the last 48 hours to explain Babcock & Wilcox's 27% gain on August 10, 2026. The jump likely reflects either delayed market reaction to an announcement, a technical/short-squeeze event, or sector-driven momentum in nuclear or energy infrastructure stocks.

The absence of any recent news headlines makes it impossible to pinpoint a specific catalyst for this substantial single-day move. Babcock & Wilcox is an industrial company focused on energy and nuclear technology, sectors that can be sensitive to regulatory developments, contract awards, policy shifts, or broader market sentiment changes. Without headlines, the most plausible explanations fall into a few categories: first, a material announcement may have occurred outside the 48-hour window but is now being priced in; second, the stock could be experiencing a technical rebound or short-squeeze if it had been oversold; third, sector-wide tailwinds in nuclear energy (a policy focus area) could be lifting the name; fourth, an earnings report or investor day could have occurred. However, these remain speculative. The rank as the 18th biggest gainer suggests this was a noteworthy but not extreme market reaction, pointing more toward fundamental news than pure technical volatility.

OBX

Obsidian Therapeutics, Inc.Healthcare

$34.91+$7.41

+26.9%

NASDAQ · Mkt cap $1.1 B

No news headlines were available in the last 48 hours, so the 26.93% jump cannot be attributed to a specific disclosed event. The move likely reflects either a clinical trial outcome announcement, regulatory decision, or market rumor that has not yet appeared in the tracked news feed.

OBX jumped nearly 27% on August 10, 2026, but the Yahoo Finance RSS feed returned no headlines in the preceding 48 hours. This disconnect suggests either a real-time announcement (such as clinical data, FDA feedback, or partnership news) that has not yet propagated to the tracked sources, or a market reaction to delayed information. Obsidian Therapeutics is a clinical-stage biotech company, making it highly sensitive to trial results, regulatory communications, and funding announcements. The magnitude of the move is consistent with positive clinical or regulatory catalysts typical in this sector. Without the actual news, attribution remains speculative, though biotech gainers of this size often correlate with Phase trial readouts or regulatory approvals.

INHD

Inno Holdings Inc.Basic Materials

$6.57+$1.38

+26.6%

NASDAQ · Mkt cap $36 M

No headlines were published in the last 48 hours for INHD, so the 26.59% gain cannot be directly attributed to news. The jump may be driven by technical factors, rumor, or delayed disclosure of a material announcement.

The absence of any Yahoo Finance headlines in the past two days for a stock that ranked 20 in daily gainers is notable. Without documented news catalysts, the move could reflect several non-news-driven scenarios: technical breakout or short covering, social media buzz or retail interest, options expiration mechanics, or delayed public disclosure of a corporate event such as a merger, capital raise, or strategic partnership that markets learned about through unofficial channels before formal announcement. Smaller-cap companies like Inno Holdings can experience outsized moves on limited volume and speculative positioning. It is also possible that relevant news exists but was not captured by this RSS feed or was published outside the 48-hour window.

ARTW

Art's-Way Manufacturing Co IncIndustrials

$2.86+$0.56

+26.3%

NASDAQ · Mkt cap $16 M

Art's-Way Manufacturing announced a significant increase in backlog from major modular building project awards on August 10, 2026, directly triggering the 26.29% single-day gain as investors responded to improved revenue visibility.

The company disclosed a "significant increase in backlog following award of major modular building projects" on the same day as the stock's 26.29% jump to $2.86. This is a concrete positive catalyst: new major project awards expand forward revenue visibility and suggest operational momentum in what appears to be a diversified manufacturing business serving agricultural and research markets. The timing correlation between the announcement release (18:00 UTC on August 10) and the intraday price action is consistent with market reaction to material business news. At a rank of 21 biggest gainer on the day, the stock likely benefited from both the headline news and momentum trading among micro-cap equities. The newsflow establishes both the event and a plausible economic rationale for the move, though the full financial magnitude of the backlog and its impact on margins remain unknown from the summary provided.

PLBY

PLBY Group, Inc.Consumer Cyclical

$1.21+$0.31

+26.1%

NASDAQ · Mkt cap $146 M

PLBY surged 26% following second quarter 2026 earnings that showed 11% revenue growth to $31.2M, net income improvement of $7.9M to $0.2M, and Adjusted EBITDA doubling to $7.0M, beating market expectations.

The earnings release demonstrates a meaningful operational turnaround. Revenue growth of 11% combined with a dramatic 100% increase in Adjusted EBITDA signals improving margins and profitability. The $7.9M swing to a $0.2M net profit suggests the company has moved past prior losses and achieved positive earnings momentum. The stock's ranking as the 22nd biggest gainer indicates this result exceeded investor expectations for a micro-cap entertainment and lifestyle brand. The mention of litigation costs of $0.7M within the EBITDA figure provides transparency on headwinds being managed. For a stock trading at $1.21, quarterly profitability combined with accelerating EBITDA growth likely triggered substantial short covering and value-seeking buying.

AREN

The Arena Group Holdings, Inc.Communication Services

$2.21+$0.45

+25.7%

NYSE · Mkt cap $50 M

The Arena Group announced a rebrand to Paradium.AI, a strategic acquisition of InfoSentience, debt refinancing, and launch of Cutter Studios on August 10, driving a 25.71% single-day gain likely reflecting investor optimism about the company's AI-focused pivot and operational restructuring.

The company released two coordinated announcements on the same date: a Q2 2026 earnings report paired with a corporate rebrand from The Arena Group to Paradium.AI, completion of the InfoSentience acquisition to scale data-driven content generation, debt refinancing, and the launch of Cutter Studios. These are substantive corporate actions signaling a strategic shift toward AI and technology capabilities. The rebrand alone combined with a named acquisition and debt cleanup typically signal management confidence and a repositioning narrative that can attract both existing shareholders and new institutional interest. The stock's rank as the 23rd biggest gainer suggests broad market recognition of the announcement. However, the headlines provided do not include actual financial metrics (earnings beat, revenue guidance, margin improvements) or explicit acquisition financial terms, so the jump may partially reflect market enthusiasm for the narrative rather than disclosed quantitative outperformance.

UPC

Universe Pharmaceuticals INCHealthcare

$6.84+$1.37

+25.2%

NASDAQ · Mkt cap $3.5 M

No news headlines were found in the last 48 hours for Universe Pharmaceuticals, so the 25% intraday gain likely reflects either a delayed market reaction to an untracked announcement, technical or short-covering activity, or retail momentum in a small-cap biotech stock.

The absence of any recent news in the provided feed makes it difficult to pinpoint a specific catalyst. Small-cap pharmaceutical stocks like UPC often experience large single-day moves on limited volume without corresponding headline coverage, particularly if the news breaks outside major newswires or is disseminated directly by the company. Common drivers for biotech gainers of this magnitude include clinical trial data releases, FDA decisions, partnership announcements, or insider buying activity. Alternatively, the move could reflect technical factors such as short covering, options expiration gamma effects, or retail investor momentum. Without headline corroboration, any explanation remains speculative rather than evidence-based.

ZVZZT

$38.55+$7.63

+24.7%

VEEE

Twin Vee Powercats Co.Consumer Cyclical

$10.53+$2.06

+24.2%

NASDAQ · Mkt cap $6.2 M

No news headlines were published in the last 48 hours, so the 24.25% jump in Twin Vee Powercats stock likely stems from technical factors, a delayed market reaction to older news, or untracked catalysts.

The absence of recent headlines makes it difficult to pinpoint a specific catalyst for this strong single-day gain. Twin Vee Powercats is a small-cap boat manufacturer, and such stocks can be responsive to sector sentiment shifts, analyst upgrades, earnings surprises from prior reporting, or insider activity that may not immediately appear in major news feeds. The jump could also reflect short covering if the stock has significant short interest, a common driver of outsized moves in lower-liquidity names. Without access to earnings calendars, SEC filings released today, or real-time trading data, the most honest assessment is that the cause remains unconfirmed by the available evidence.

AACBR

Artius II Acquisition Inc. Rights

$0.12+$0.02

+24.1%

NASDAQ

No news headlines were found in the last 48 hours, so the 24% gain on AACBR (a SPAC rights offering) likely reflects either a technical bounce in a thinly traded security, momentum in the underlying SPAC, or market activity unrelated to fundamental news.

AACBR is a rights offering associated with Artius II Acquisition Inc., a special purpose acquisition company. Rights offerings in SPACs are inherently volatile and thinly traded securities, often showing significant price swings on modest volume or technical factors rather than news-driven catalysts. The absence of any news headlines in the last 48 hours suggests this move was not triggered by an announced business combination, earnings report, or major corporate action. In such cases, gains on SPAC-related securities typically reflect either short covering in a low-volume name, retail momentum trading, technical chart bounces after prior weakness, or spillover sentiment from the broader SPAC market or the underlying SPAC's recent activity. Without headline confirmation, attribution remains speculative.

NESR

National Energy Services Reunited CorpEnergy

$35.76+$6.66

+22.9%

NASDAQ · Mkt cap $3.4 B

NESR jumped 22.89% following a strong Q2 2026 earnings beat announced on August 10, with record revenue of $520.8 million (59.1% YoY growth), EPS beating estimates by 29.1%, and the company hitting a $2 billion annualized run-rate milestone ahead of schedule.

National Energy Services Reunited reported exceptional second-quarter results that significantly exceeded Wall Street expectations. Revenue topped estimates by 13.60% while earnings per share beat by 25.71%, with absolute figures showing $520.8 million in sales and $0.43 GAAP profit per share. The company also announced it has reached a $2 billion annualized revenue run-rate earlier than previously guided, driven by Jafura ramp-up and strategic expansion initiatives. Management initiated shareholder returns, signaling confidence in cash generation. The broader energy sector also advanced 3.4 to 3.8% on August 10, providing a tailwind. While the headlines note geopolitical conflict in key markets, the operational execution and forward guidance appear robust enough to drive the stock substantially higher despite these headwinds.

HYFM

Hydrofarm Holdings Group, Inc.Industrials

$1.93+$0.36

+22.5%

NASDAQ · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 22.54% jump is unexplained by reported corporate developments. The move may reflect technical trading, market sentiment shifts, or delayed news absorption.

Hydrofarm is a horticultural equipment and supplies company, and a 22.54% single-day move without accompanying headlines is notable. In micro-cap and small-cap agricultural technology stocks, sharp moves often occur from several categories: short covering or technical rebounds after recent declines, sector-wide sentiment shifts (e.g., cannabis or indoor farming industry tailwinds), delayed disclosure of material events, options-driven activity, or retail trading concentration. Without access to pre-market news, earnings surprises announced after market close the prior day, SEC filings, or social media catalysts, the immediate cause remains opaque. The absence of news in the 48-hour window does not prove nothing happened—it may indicate the catalyst was too recent, embedded in a filing rather than a press release, or localized to trading chat rather than major news aggregators.

MGRX

Mangoceuticals, Inc. - Common StockHealthcare

$0.60+$0.11

+22.5%

NASDAQ · Mkt cap $7.2 M

No news headlines were found in the last 48 hours, so the 22.5% gain on MGRX cannot be directly attributed to a specific company announcement or event based on available evidence.

The absence of recent news headlines makes it difficult to pinpoint a definitive cause for the stock's sharp 22.5% one-day gain. For a micro-cap stock like MGRX trading at $0.60, price movements of this magnitude are not uncommon and can be driven by several factors: technical or algorithmic trading on low volume, short covering or squeeze dynamics, retail social media attention, delayed news dissemination that hasn't yet appeared in major RSS feeds, or company announcements made through less mainstream channels. Given that MGRX appears to be a small healthcare or supplement-focused company based on its name, the move could theoretically relate to product announcements, clinical or regulatory developments, or partnership news, but without corroborating headlines this remains speculation rather than explanation.

NUTX

Nutex Health, Inc.Healthcare

$198.05+$35.57

+21.9%

NASDAQ · Mkt cap $1.4 B

No news headlines were found in the last 48 hours for Nutex Health, so the 21.89% gain cannot be directly attributed to a reported event. The jump may reflect technical trading activity, delayed news processing, or market speculation.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means we cannot identify a specific fundamental catalyst for this 21.89% spike in NUTX. This is noteworthy because such a large single-day gain typically correlates with material announcements like earnings surprises, clinical trial results, partnership deals, or regulatory approvals, particularly for healthcare-focused stocks. Without access to company press releases, social media activity, or real-time trading data, several possibilities exist: the move could be driven by short covering or momentum trading, a delayed market reaction to earlier news not yet indexed in the RSS feed, rumors not yet formalized as public announcements, technical breakout trading, or sector-wide momentum in healthcare or specialty healthcare providers. Without direct evidence, attributing this move to any specific cause would be speculation.

FutureFuel CorpBasic Materials

$5.17+$1.11

+21.8%

NYSE · Mkt cap $250 M

FutureFuel announced Q2 2026 results on August 10, which likely drove the 21.81% gain, though the headline snippet does not disclose the specific earnings figures or forward guidance that presumably beat expectations.

The timing alignment between the earnings announcement (2026-08-10 20:15:00 UTC) and the large intraday gain strongly suggests the results were the catalyst. However, the provided headline is only a press release header without financial details, earnings-per-share figures, revenue, margin data, or management commentary. A 21.81% jump on a chemical and biofuels manufacturer typically reflects either a significant earnings beat, raised guidance, a strategic announcement embedded in the results, or notably improved segment profitability. Without the actual numbers or commentary in the headline text, we can infer the results were favorable, but cannot isolate which specific metric or forward statement drove the magnitude of the move.

TGHL

The GrowHub Limited Class A Ordinary SharesTechnology

$0.99+$0.18

+21.7%

NASDAQ · Mkt cap $17 M

No news headlines were found in the last 48 hours, so the +21.66% jump to $0.99 appears driven by factors other than published announcements. The move may reflect technical trading, delayed news dissemination, or market sentiment in a low-priced micro-cap stock.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for this 21.66% gain. TGHL is a micro-cap security trading under one dollar, a category historically prone to technical momentum, short-covering, and retail trading activity rather than fundamental news flow. Possible drivers include delayed earnings or guidance, an untracked corporate action, viral retail interest, or a rebound from oversold conditions. Without access to real-time social media, press release databases, or the company's investor relations channels, identification of the actual cause remains speculative. The stock's very low price and high volatility make it susceptible to outsized moves on modest dollar volume.

GRI

Cohen & Steers Global Realty Majors ETFHealthcare

$1.72+$0.31

+21.2%

NASDAQ · Mkt cap $3.1 M

No news headlines were found in the last 48 hours to explain the 21.23% gain in GRI, so the driver remains unclear and could reflect a broad real estate sector rebound, technical positioning, or delayed market reaction to prior events.

GRI is an ETF holding major global real estate stocks, and without recent news coverage the move cannot be attributed to a specific announcement, earnings release, or named catalyst. A 21% single-day jump in a large-cap real estate ETF is substantial and could reflect several types of triggers. First, the broader real estate or financial sector may have rallied on economic data, interest rate signals, or sentiment shifts that would naturally lift a diversified REIT fund without requiring company-specific news. Second, the move could be technical in nature—such as short covering, fund rebalancing, or options-related activity—especially if GRI had been underperforming. Third, there may have been news released before the 48-hour window or institutional position adjustments that took time to show up in price. Without explicit headlines or known structural catalysts tied to the ETF itself, the specific driver cannot be identified with confidence.

FSLY

Fastly IncTechnology

$27.75+$4.78

+20.8%

NYSE · Mkt cap $3.3 B

Fastly shares surged 20.81% on August 10, 2026, driven by a shift in AI-cloud sector dynamics that the headline suggests is unexpected, but the specific catalyst is not disclosed in the available news summary.

The Yahoo Finance headline confirms that Fastly is having one of its biggest single-day rallies of the year and references a "shifting dynamic across the entire AI-cloud sector" that investors may not have anticipated. However, the headline does not specify the actual catalyst—no earnings report, guidance change, product announcement, partnership, or market-moving event is named. The phrasing suggests either a broad sector rotation in favor of edge-computing or CDN infrastructure plays, or a company-specific positive development that the headline teases but does not detail. Without access to the full article text, the precise reason remains unclear. Fastly is a cloud infrastructure and edge-computing provider, so typical catalysts would include strong quarterly results, new customer wins, margin improvements, or recognition of AI workload demand shifting to edge networks rather than centralized clouds.

POWW

AMMO, Inc.Industrials

$2.56+$0.43

+20.2%

NASDAQ · Mkt cap $265 M

POWW jumped 20% on strong Q1 fiscal 2027 earnings released today, with revenue up 22%, adjusted EBITDA surging 152%, and both earnings and revenue beating estimates by significant margins.

Outdoor Holding Company reported first-quarter fiscal 2027 results that exceeded analyst expectations substantially. Revenue surged 22% year-over-year, while adjusted EBITDA more than doubled to $7.9 million, a 152% increase driven by record marketplace activity and the successful launch of its FFL transfer service. The company also posted earnings and revenue surprises of 200% and 12.25% respectively against consensus estimates. Additionally, the company appears to have achieved a materially lower operating-cost base through restructuring. These results represent a significant operational inflection point for the company, combining top-line growth acceleration with substantial margin expansion and cost discipline, which explains the substantial single-day appreciation.

ATXG

Addentax Group CorpIndustrials

$4.68+$0.78

+20.0%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours, so the 20% gain likely stems from technical trading activity, delayed announcement coverage, or an untracked catalyst specific to this micro-cap stock.

The absence of recent news headlines makes it impossible to point to a specific corporate event or disclosure as the cause of ATXG's sharp 20% gain. Addentax Group Corp is a small-cap NASDAQ-listed company, and stocks in this category can experience outsized moves on light volume from technical factors such as short covering, momentum trading, or retail interest in low-priced stocks. Alternatively, a news event may have occurred but not yet propagated through major financial news feeds, or the catalyst could be company-specific news released through channels not captured by standard RSS feeds. Without access to company announcements, insider trading filings, or real-time social media chatter, determining the root cause is not possible from the data provided.

VERU

Veru IncHealthcare

$2.78+$0.46

+19.6%

NASDAQ · Mkt cap $45 M

Veru reported that its Phase 2b PLATEAU clinical trial for a weight-loss drug combination is fully enrolled with 239 patients and on track for interim results, likely driving the 19.61% gain on clinical trial progress momentum.

The single headline from 2026-08-10 indicates Veru announced completion of patient enrollment in its Phase 2b PLATEAU trial testing enobosarm combined with semaglutide for weight loss, with interim analysis expected on schedule. For a clinical-stage biotech stock, full enrollment of a late-stage trial is typically viewed as a de-risking milestone, especially when paired with explicit confirmation that results remain on track. The timing of this announcement coinciding with the +19.61% jump suggests investor confidence in the trial's progression. The headline does not provide detail on efficacy signals, safety concerns, or the specific timeline for interim data, so the move reflects optimism about trial execution rather than clinical success itself.

MWYN

Marwynn Holdings, Inc. Common stockConsumer Cyclical

$0.85+$0.14

+19.6%

NASDAQ · Mkt cap $21 M

No headlines were published in the last 48 hours, so the 19.6% gain on MWYN cannot be attributed to reported news. The move likely reflects technical buying, short covering, or an untracked announcement.

The absence of recent news headlines makes it impossible to identify a specific catalyst for the stock's strong gain. Penny stocks and thinly traded securities like MWYN often experience sharp moves on minimal volume driven by technical factors rather than fundamental news. Possible explanations include: (1) a short squeeze or covering event, which can push low-priced stocks up sharply when few shares are available to purchase, or (2) delayed disclosure of company news that has not yet propagated to major news feeds. A third possibility is that a material announcement was made through press release or SEC filing but has not yet appeared in standard news aggregators. Without access to real-time SEC filings, press releases, or social media channels, we cannot determine which of these scenarios occurred.

PAVS

Paranovus Entertainment Technology Ltd. - Class A Ordinary SharesConsumer Defensive

$7.55+$1.15

+19.2%

NASDAQ · Mkt cap $5.5 M

No news headlines were found in the last 48 hours, so the 19.17% jump in PAVS cannot be directly attributed to a publicly reported event. The move likely reflects either a delayed market reaction to an unreported announcement, a technical or speculative catalyst, or retail trading activity.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for PAVS's strong gain. Paranovus Entertainment Technology is a relatively small-cap equity, and such stocks can experience sharp moves on limited volume driven by several mechanisms: a delayed market reaction to an announcement not yet captured in news feeds, short-covering or technical breakout, rumors circulating on social media or trading forums without formal disclosure, insider accumulation signals, or simple speculative interest in the entertainment technology sector. Without access to intraday volumes, after-hours activity, or SEC filings from the past 48 hours, attributing the move to any single cause would be pure speculation.

STFS

Star Fashion Culture Holdings LimitedCommunication Services

$4.09+$0.68

+19.1%

NASDAQ · Mkt cap $5.3 M

No news headlines were available in the last 48 hours to explain STFS's 19.14% gain, so the driver remains unclear; the jump may reflect technical trading, delayed news dissemination, or market-moving developments not yet captured in the RSS feed.

The absence of recent news in the provided RSS feed makes direct attribution impossible. STFS is a fashion retail holding company with relatively modest liquidity on NASDAQ, which can exhibit outsized moves on modest volume or sentiment shifts. For stocks in this category, significant daily jumps often stem from several possible sources: a delayed earnings release or guidance revision that hasn't yet propagated to the headline feed, short covering if the stock has notable short interest, technical breakout from support or moving averages, rumors or social media activity not yet formalized in news, or sector-wide momentum in apparel retail. Without access to trading volume, short interest data, or company filings from the relevant date, we cannot definitively isolate which mechanism drove today's move.

MGN

Megan Holdings LimitedIndustrials

$0.13+$0.02

+18.6%

NASDAQ · Mkt cap $3.7 M

No news headlines were available in the last 48 hours, so the +18.60% gain cannot be tied to a specific announced catalyst. The move likely reflects technical trading, retail interest, or delayed news dissemination.

The absence of recent news headlines for MGN makes it impossible to pinpoint a fundamental cause for the 18.60% single-day jump. Micro-cap stocks like this one, trading at $0.13 per share, are frequently subject to technical factors, short-covering rallies, or retail-driven momentum independent of news flow. The stock's ranking as the 42 biggest gainer suggests it was part of a broader retail or algorithmic trading wave. Possible explanations include a delayed press release that has not yet surfaced in Yahoo Finance RSS feeds, short-squeeze activity, options-driven positioning, or simply rotational interest within the penny-stock sector. Without headline evidence or structural data about MGN's business, capital structure, or insider activity, any specific catalyst remains speculative.

FTH

Faeth Therapeutics, Inc.Healthcare

$28.82+$4.52

+18.6%

NASDAQ · Mkt cap $1.0 B

No news headlines were found in the last 48 hours, so the 18.59% gain is not directly explained by any reported event. The move may reflect delayed market reaction to an earlier announcement, technical factors, or market rumors not yet captured in major news feeds.

Faeth Therapeutics, a clinical-stage biotech firm, jumped 18.59% today with no corresponding headlines in the Yahoo Finance RSS feed over the past two days. This disconnect suggests either a timing lag in news dissemination, a market reaction to pre-market or after-hours developments not yet reflected in mainstream headlines, or buying pressure driven by technical factors or social media discussion. Small-cap biotech stocks are particularly sensitive to clinical trial results, regulatory communications, partnership announcements, or insider activity. Without confirmed news, it is reasonable to hypothesize the move stems from a catalyst in one of these categories, but this remains inference rather than established fact. The absence of headlines does not exclude the possibility that material information was released through a press release or SEC filing that has not yet propagated to news aggregators.

LIMN

Iris Acquisition CorpHealthcare

$0.12+$0.02

+18.5%

NASDAQ · Mkt cap $9.4 M

No news headlines were published in the last 48 hours, so the 18.54% gain on LIMN cannot be attributed to a specific announced event. The move is likely driven by technical factors, delayed news, or market activity specific to this blank-check company.

Iris Acquisition Corp is a SPAC with no reported headlines in the past two days to explain the intraday jump. SPACs and shell companies can experience sudden price movements from several sources: technical trading or short covering on low float and liquidity, insider activity or merger negotiations not yet publicly disclosed, delayed dissemination of news from wire services, or retail trading interest. The stock's very low price of $0.12 and rank as the 44th biggest gainer suggest retail participation may be a factor. Without access to Level 2 data, after-hours activity, or company filings released on or before August 10, it is impossible to determine whether the move reflects fundamental news, a rumor, or purely technical repositioning.

ACDC

ProFrac Holding CorpEnergy

$5.11+$0.79

+18.2%

NASDAQ · Mkt cap $920 M

ProFrac reported Q2 revenue that beat expectations, and although sales were flat year-over-year, the positive earnings surprise combined with strategic upgrades likely drove the 18% gain on a day when the stock ranked among the top 45 gainers.

The headline confirms that ProFrac delivered Q2 results that topped market revenue expectations, hitting $498.1 million. While the company faced headwinds with flat year-over-year sales growth, the fact that it beat consensus estimates is a concrete positive catalyst in a cyclical industry like hydraulic fracturing services. The mention of "strategic upgrades" and "market discipline" suggests management signaled either operational improvements or favorable forward positioning despite industry volatility. For a small-cap services provider like ACDC, beating earnings expectations can trigger meaningful short-term buying, especially if the market had set a low bar given broader energy sector uncertainty. The timing of the announcement on August 10 aligns with the trading spike, making this a news-grounded move rather than speculation about external factors.

Everpure, Inc.Technology

$98.01+$15.92

+17.8%

NYSE · Mkt cap $35 B

Everpure announced a design win with a second top-five hyperscaler on August 10, and the broader IT hardware sector is benefiting from accelerated enterprise spending driven by memory price increases, directly catalyzing the 17.77% gain.

Everpure's announcement of a new design win and supply agreement with a second top-five hyperscaler is the most direct and company-specific catalyst for the stock's strong performance. This represents a significant commercial milestone for the storage and data management company, expanding its footprint with major cloud infrastructure operators. The timing coincides with a sector-wide tailwind: Morgan Stanley upgraded its view on IT hardware on August 10, arguing that memory price increases and "chipflation" are accelerating rather than delaying enterprise infrastructure spending. This macro backdrop validates demand for storage solutions and positions companies like Everpure favorably within the hardware spending cycle. The combination of a named customer win plus supportive sector commentary created a catalytic event for the stock.

CBAT

CBAK Energy Technology IncIndustrials

$0.77+$0.11

+17.5%

NASDAQ · Mkt cap $62 M

No news headlines were found in the last 48 hours for CBAT, so the 17.49% gain lacks an identifiable catalyst in the available record. The move may reflect technical trading, delayed news pickup, or sector momentum.

CBAK Energy Technology is a battery manufacturer, and the absence of any news in the Yahoo Finance RSS over the last two days means we cannot point to a specific earnings report, product announcement, partnership, or regulatory action as the driver of today's gain. For micro-cap and small-cap stocks trading on NASDAQ, price moves of this magnitude without accompanying headline news are not uncommon and can arise from several categories of causes: technical rebounds after prior weakness, short-covering if the stock had elevated short interest, sector-wide momentum in battery or energy stocks, delayed wire service picks up of older news, or simply lower trading volume amplifying retail or algorithmic activity. Without corroborating headlines or structural information about CBAT's current short interest or technical setup, we cannot distinguish between these scenarios.

FCRS.WT

FutureCrest Acquisition Corp. WT

$0.86+$0.12

+16.7%

SAFX

XCF Global, Inc.Utilities

$0.44+$0.07

+16.5%

NASDAQ · Mkt cap $141 M

XCF Global announced strong renewable fuel credit market conditions with D4 RIN values exceeding $3.50 per gallon, likely driving investor optimism about the company's near-term revenue and margins in this sector.

On August 10, 2026, XCF Global issued a press release highlighting strength in the renewable fuel credit (RIN) market, specifically noting that D4 RIN values have risen to levels representing more than $3.50 per gallon. This is a material development for a company operating in the renewable fuels space, as higher RIN prices directly improve the economics of renewable fuel producers and credit traders. The timing of the announcement on the day of the 16.51% gain suggests investors responded positively to evidence of favorable market conditions. The headline does not disclose new contracts, earnings beats, or guidance changes, but rather frames the announcement as highlighting existing market strength that benefits the company's business. This type of commodity-price-positive news typically resonates with small-cap energy and renewables stocks trading at modest valuations.

DKI

DARKIRIS INCCommunication Services

$4.26+$0.62

+16.5%

NASDAQ · Mkt cap $8.5 M

No news headlines were found in the last 48 hours, so the 16.49% gain cannot be attributed to a disclosed catalyst. The move is likely driven by technical trading, delayed news dissemination, or undisclosed market factors.

The absence of recent news is notable given DKI's 16.49% single-day jump to rank 50th among gainers. Without access to real-time market data, SEC filings, or delayed news sources beyond the provided RSS feed, the cause remains unclear. Possible explanations in this category of low-information scenarios typically include technical breakouts or short-covering in smaller-cap stocks, insider activity not yet reflected in public headlines, late-breaking announcements from investor relations that haven't propagated to major news feeds, or broader sector rotation. For a smaller-cap stock like DKI, even modest volume shifts can produce outsized percentage moves. However, these are hypotheses about the type of catalyst, not confirmations of any actual event.

Biggest Losers

Mon, Aug 10, 2026 50

SION

Sionna Therapeutics, Inc. Common StockHealthcare

$4.49−$45.25

-91.2%

NASDAQ · Mkt cap $282 M

Sionna Therapeutics' cystic fibrosis drug candidate SION-719 failed to meet its primary endpoint in a Phase 2a clinical trial, eliminating the company's most advanced pipeline asset and triggering a 91% stock collapse.

The news headlines establish a clear and devastating catalyst: on August 10, 2026, Sionna announced that SION-719 missed the main goal in its PreciSION CF Phase 2a trial in adults with cystic fibrosis already taking Vertex's Trikafta. This represents a catastrophic clinical failure for what appears to have been the company's lead program. For a biotech firm with a single or heavily concentrated pipeline, failure of a mid-stage trial for a major indication typically destroys shareholder value instantly because it eliminates near-term revenue prospects and raises questions about the company's ability to generate viable products. The secondary effect visible in the news is that Vertex Pharmaceuticals stock surged 5.9% because Sionna's failure removes a competitive threat to Vertex's cystic fibrosis franchise. The stock's 91% decline reflects the market's assessment that the failed trial has rendered the company's core asset worthless or substantially impaired.

TENX

Tenax Therapeutics IncHealthcare

$1.37−$11.85

-89.1%

NASDAQ · Mkt cap $71 M

Tenax Therapeutics stock crashed 89% after its Phase 3 LEVEL trial for TNX-103 failed to meet its primary endpoint of improving exercise capacity in pulmonary hypertension patients, eliminating a key near-term catalyst for the company.

The evidence is straightforward and definitive. On August 10, 2026, Tenax announced that TNX-103, its lead candidate in late-stage development for a significant indication (pulmonary hypertension with heart failure with preserved ejection fraction), missed the primary efficacy endpoint in its pivotal Phase 3 trial. The drug also failed to show improvement in a key secondary symptom endpoint. For a small-cap biotech company with limited pipeline diversity, failure of a Phase 3 program typically removes substantial intrinsic value because it eliminates the path to near-term revenue and regulatory approval. The 89% single-day decline is typical for such catastrophic clinical failures, as investors immediately reprice the company's probability of success and near-term prospects. The news headlines confirm this was the direct and immediate catalyst for the move.

ACH

Aluminum Corp of China LtdHealthcare

$1.40−$1.38

-49.6%

NYSE · Mkt cap $102 M

Accendra Health (ACH) plummeted nearly 50% on news of CEO Edward Pesicka's retirement announcement, combined with adoption of a tax asset preservation plan and Q2 earnings results released the same morning.

Three material announcements arrived within minutes on August 10, 2026. The most significant catalyst appears to be the immediate departure of President and CEO Edward Pesicka, with the board beginning a successor search but no interim replacement named. Leadership transitions of this magnitude typically trigger sharp selloffs, particularly when announced abruptly without clear succession planning. Simultaneously, the company adopted a Section 382 Rights Agreement (poison pill) to protect tax loss carryforwards, a defensive measure that often signals distress. Q2 2026 financial results were also disclosed at 10:45 UTC but the headlines provided do not include actual earnings figures, margins, or guidance changes that would explain the magnitude of decline. Investors likely interpreted the CEO departure as the primary negative catalyst, with the tax preservation plan reinforcing concerns about the company's financial health or vulnerability to acquisition attempts at depressed valuations.

AIRS

AirSculpt Technologies, Inc.Healthcare

$2.74−$2.28

-45.4%

NASDAQ · Mkt cap $203 M

AirSculpt reported Q2 revenue that missed expectations and issued weaker forward EBITDA guidance, triggering a sharp 45% sell-off after an initial 13% intraday drop on the earnings miss.

The headlines establish that AirSculpt released second-quarter earnings on August 10, 2026, with revenue of $42.9 million, down 2.5% year-over-year. While the company highlighted positive same-center case growth of 1% and characterized revenue trends as stable, the market appears to have reacted negatively to two factors: the revenue decline itself and notably weaker EBITDA guidance going forward. The initial 13% drop mentioned in the midday headline preceded an even larger final decline to 45%, suggesting the market may have revised expectations downward as more details from the earnings call became available. For a medical aesthetics company trading at a low absolute price, earnings misses and guidance reductions typically trigger swift and severe repricing. The persistence of revenue decline despite positive same-center metrics suggests margin pressures or unit economics concerns that spooked investors.

VATE

Elev8 Brands, IncIndustrials

$7.26−$4.95

-40.5%

NYSE · Mkt cap $107 M

VATE fell 40.52% on August 10 despite Q2 earnings showing strong revenue growth of 74.2% and record infrastructure segment performance reported on August 9, suggesting the market's reaction may reflect guidance disappointment, margin concerns, or forward guidance that contradicted the headline ea…

The provided headline confirms VATE reported Q2 2026 revenue of $421.6 million, a significant 74.2% year-over-year increase, with record revenue and widened margins in the Infrastructure segment plus backlog growth. However, the earnings call highlights are truncated and do not include management's full-year guidance, margin commentary beyond "wider margins," or forward-looking statements. A 40% single-day drop following a revenue beat and positive operational metrics typically signals either (1) guidance that disappointed relative to pre-announcement expectations, (2) disclosure of margin compression or rising costs offset by the headline revenue growth, or (3) a significant drop in backlog dollar value or booking rate. The incomplete headline leaves the specific catalyst unconfirmed.

QTRX

Quanterix CorpHealthcare

$2.41−$1.62

-40.2%

NASDAQ · Mkt cap $140 M

Quanterix reported Q2 earnings that beat on revenue growth (34% YoY) but slashed full-year 2026 guidance to $142–148 million due to commercial execution challenges and broad market softness, pushing cash-flow break-even from 2026 to 2027, triggering the severe sell-off.

The stock's 40% single-day decline directly correlates with Quanterix's earnings announcement and forward guidance cut. While Q2 revenue of $32.9 million showed solid 34% year-over-year growth, management's acknowledgment of "broad-based market softness" and "commercial execution challenges" prompted a material reduction in full-year expectations and delayed cash-flow profitability by one year. The company also announced a new Chief Commercial Officer on the same day, which could signal either a corrective leadership move or simply coincide with broader disappointment. For a pre-profitable biotech company, guidance cuts—especially those that push profitability timelines further out—typically trigger sharp multiple compression and signal investor loss of confidence in near-term monetization.

TOPP

Toppoint Holdings Inc.Industrials

$0.29−$0.19

-39.2%

NYSE · Mkt cap $5.3 M

No news headlines were reported in the last 48 hours for TOPP, so the 39% single-day loss cannot be attributed to any identified public catalyst; the cause remains unknown without additional context.

The absence of recent news is striking given the severity of the move. A 39% single-day decline in a micro-cap stock like TOPP typically correlates with a material negative catalyst such as earnings disappointment, guidance withdrawal, insider selling disclosure, regulatory action, or a capital restructuring announcement. Without any headline evidence, the cause could fall into several categories: delayed market reaction to an older announcement, intraday rumor or social media event not yet captured in traditional financial news feeds, technical liquidation or forced selling (common in penny stocks), short seller targeting, or an after-hours or pre-market news release that had not yet been indexed when this snapshot was taken. The lack of liquidity in sub-dollar stocks can also amplify moves on thin volume.

NABL

N-able, Inc.Technology

$3.21−$1.78

-35.7%

NYSE · Mkt cap $754 M

N-able reported Q2 earnings that met estimates with 6% ARR growth but slashed full-year guidance due to weaker-than-expected renewal rates in its unified endpoint and EDR products, triggering the 35.71% sell-off.

N-able's earnings results on August 10, 2026 presented a mixed picture that the market penalized heavily. While the company beat on revenue (+0.11% surprise) and met earnings estimates, the headline catalyst was the full-year guidance reduction announced during the earnings call. The company cited renewal challenges specifically in its unified endpoint management (UEM) and endpoint detection and response (EDR) product lines as the reason for lowering forward guidance. In subscription and SaaS-heavy software companies, renewal rates and forward guidance are often more important to valuation than current-quarter results, since they signal recurring revenue sustainability. A guidance cut of this magnitude, especially attributing it to product-specific weakness rather than macro headwinds, appears to have triggered substantial institutional selling, placing NABL among the day's worst performers despite meeting current expectations.

CLRO

ClearOne IncTechnology

$8.95−$3.78

-35.7%

NASDAQ · Mkt cap $13 M

No news headlines were available in the last 48 hours, so the 35.66% drop cannot be directly attributed to a disclosed event. The decline likely stems from an undisclosed earnings miss, guidance cut, or market-wide sell-off in the audio/conferencing sector.

ClearOne is a maker of audio and visual communication equipment serving enterprise and professional markets. The absence of any news in the provided headlines over the last 48 hours means the catalyst for this severe single-day decline is not immediately documented in public announcements. For a stock experiencing a top-ten loss of this magnitude, the most probable explanations fall into a few categories: an earnings announcement or guidance reduction that may have been released but not yet captured in the RSS feed lag, an unannounced material negative development disclosed in an 8-K or press release, weakness in enterprise spending or customer concentration issues, or broader sector rotation out of audio/conferencing hardware. Without documented headlines, we cannot confirm which factor applies.

EVTL

Vertical Aerospace Ltd.Industrials

$0.91−$0.46

-33.9%

NYSE · Mkt cap $132 M

Vertical Aerospace announced a $100 million financing commitment on the same day competitor Archer jumped on Boeing's aerospace subsidiary acquisition, suggesting market rotation away from EVTL toward stronger consolidated rivals in the air taxi space.

Vertical Aerospace released positive news on August 10 announcing approximately $100 million in financing commitments to advance certification and commercialization of its electric aircraft. However, the stock fell 33.85%, making it the 10th biggest loser of the day. The timing coincides with major sector news: Archer Aviation agreed to acquire three Boeing aerospace subsidiaries in exchange for an equity stake, triggering a sharp rally in Archer stock. This suggests the market may be repricing competitive dynamics within the urban air mobility sector. The financing announcement, while supportive of EVTL's development roadmap, may have been overshadowed by investor perception that Archer's tie-up with Boeing—providing manufacturing scale, aerospace expertise, and certification pathways—represents a significant competitive advantage. The size and severity of EVTL's decline relative to positive company-specific news points toward sector-level rotation rather than fundamental deterioration at Vertical itself.

SQFT

Presidio Property Trust IncReal Estate

$1.54−$0.75

-32.8%

NASDAQ · Mkt cap $2.1 M

No headlines were published in the last 48 hours, so the cause of the 32.75% plunge cannot be identified from news sources. The drop likely stems from earnings, guidance revision, sector rotation, or undisclosed corporate developments.

Without any news headlines in the search window, we cannot pinpoint a specific catalyst for SQFT's sharp 32.75% decline. Presidio Property Trust is a real estate investment trust, a sector sensitive to interest rate expectations, occupancy data, and dividend sustainability. A move of this magnitude in a REIT typically reflects material news: disappointing quarterly earnings, a dividend cut announcement, significant asset impairment, tenant defaults, or deteriorating property valuations. The absence of captured headlines does not mean no news broke; it may indicate the company released information outside the 48-hour window, the market reacted to analyst downgrades, or institutional selling occurred on material nonpublic information becoming public in trading. REIT stocks can also gap down sharply on sector-wide shocks or real estate market contractions.

HRTX

Heron Therapeutics IncHealthcare

$0.33−$0.15

-31.9%

NASDAQ · Mkt cap $57 M

Heron Therapeutics crashed 32% after withdrawing full-year 2026 guidance due to CINVANTI patent risks enabling generic competition and initiating a strategic alternatives review, combined with Q2 earnings that missed revenue estimates by 11% and posted a net loss.

On August 10, 2026, Heron reported Q2 net revenue of $37.7 million, a modest sequential and year-over-year increase but falling short of consensus estimates by approximately 11%. More critically, management withdrew full-year 2026 guidance citing two major concerns: potential generic competition for CINVANTI following patent challenges, and an ongoing strategic alternatives process that implies uncertainty about the company's independent future. The earnings also reflected a net loss rather than profitability. While the company noted strong growth in APONVIE sales, the combination of missed Q2 results, loss of forward visibility, patent jeopardy to a key product, and the implicit admission that a strategic review is underway all signaled deteriorating near-term prospects and potential dilution or acquisition at depressed valuations. Investors typically punish guidance withdrawals and patent threats sharply, particularly in smaller-cap biotechnology.

AIOT

PowerFleet, Inc.Technology

$3.06−$1.37

-31.0%

NASDAQ · Mkt cap $409 M

PowerFleet reported Q1 earnings that beat on EPS but missed on revenue and lowered full-year guidance, triggering a 31% sell-off as investors repriced the company on weaker forward expectations.

On August 10, 2026, PowerFleet released first-quarter fiscal 2027 results showing a contradiction: while the company achieved an earnings per share beat and reported revenue growth with higher adjusted EBITDA, it simultaneously issued a weaker full-year outlook. The company cited resource reallocation toward a rapidly expanding South African government contract as the reason for the guidance reduction. The market appears to have weighted the miss on revenue expectations and the reduced forward guidance much more heavily than the EPS beat, particularly because guidance cuts are often interpreted as management loss of confidence in near-term demand outside the single large project driving growth. The 17% intraday drop visible in headlines suggests initial selling accelerated further after market open, pushing the total loss to nearly 31% by day's end, consistent with a narrative of execution risk and concentration concerns around a major customer contract.

ZJYL

JIN MEDICAL INTERNATIONAL LTD. - Ordinary SharesHealthcare

$2.93−$1.14

-26.9%

NASDAQ · Mkt cap $24 M

No news headlines were available in the past 48 hours to explain ZJYL's 26.95% decline, making the specific catalyst unclear. The drop likely stems from either a delayed company announcement, a market-wide sector downturn, or technical selling pressure in this lower-priced microcap stock.

The absence of recent news headlines is notable given the magnitude of this decline, which ranks ZJYL as the 14th biggest loser on the day. For a medical device or pharmaceutical company trading at $2.93, a near-27% single-day drop typically correlates with material news such as clinical trial results, regulatory setbacks, earnings misses, or significant insider selling. Since no headlines appear in the 48-hour window captured by the RSS feed, either the news originated earlier and the market is digesting it with a delay, or the catalyst is a rumor, technical breakdown, or sector-wide decline not yet reflected in the headline capture. Lower-priced microcaps like ZJYL are also more prone to volatile trading on light volume and short-term momentum shifts.

CSAI

Cloudastructure, Inc. Class A Common StockTechnology

$5.42−$1.83

-25.2%

NASDAQ · Mkt cap $4.5 M

No news headlines were found in the last 48 hours, so the 25% drop on August 10 cannot be attributed to a publicly reported event. The decline likely reflects either delayed market reaction to untracked developments, technical selling, or sector headwinds affecting the infrastructure or AI softwa…

The absence of recent headlines in the provided news feed is the first constraint here. A 25% single-day drop is severe and typically tied to material news—earnings misses, revenue warnings, leadership changes, regulatory action, or significant business developments. Since none of that appears in the Yahoo Finance RSS snapshot for the preceding 48 hours, the catalyst either occurred more than 48 hours prior and the market is reacting with a lag, broke outside the tracked news sources, or involves intraday technical pressure or short covering. For a company operating in cloud infrastructure and AI (based on the name Cloudastructure), common volatility drivers include cloud spending cycles, competition from larger hyperscalers, customer concentration risk, or shifts in AI investment priorities. Without access to the specific news, those remain plausible categories but cannot be confirmed.

LINC

Lincoln Educational Services CorpConsumer Defensive

$30.79−$10.19

-24.9%

NASDAQ · Mkt cap $813 M

Lincoln Educational beat Q2 revenue and EBITDA expectations with 22.4% and 42.4% growth respectively, yet the stock fell 24.87%, likely due to investor disappointment with forward guidance or concerns about the mentioned student enrollment slowdown offsetting current strength.

The headlines establish that LINC reported better-than-expected Q2 results with record revenue growth and strong EBITDA expansion. However, multiple sources note the company acknowledged a "slower-than-expected" student start pace and only "reiterated" full-year guidance rather than raising it. This disconnect—strong historical results paired with cautious forward signals—commonly triggers sell-offs as investors repriced growth expectations downward. The earnings call likely contained commentary on margin pressures, competitive headwinds in the education sector, or challenges in student recruitment that spooked the market despite beating the quarter. A 25% single-day decline suggests either severe guidance reduction or significant forward headwind revelation that the headlines do not fully detail.

KCHVR

Kochav Defense Acquisition Corp. Right

$0.14−$0.04

-23.4%

NASDAQ

No news headlines were reported in the last 48 hours, so the 23% decline cannot be directly attributed to a specific announced event; the drop likely reflects typical volatility in SPAC or blank-check equity structures or a delayed market reaction to prior developments.

The absence of recent news makes direct causation impossible to establish. However, KCHVR is a rights unit from a SPAC acquisition vehicle (Kochav Defense), and such securities are prone to sharp price swings driven by redemption dynamics, warrant/rights conversion economics, or shifts in underlying deal sentiment. Rights offerings are highly sensitive to changes in the target company's perceived value or deal execution risk. The stock's low price of $0.14 and rank as the 17th biggest loser suggests sector-wide or company-specific pressure. Without headlines, the catalyst could be an unannounced earnings miss, a delayed regulatory filing, insider selling, or simply technical delisting pressure. For this class of security, lack of news does not mean lack of catalyst—it may indicate the market is reacting to absence of positive news or to deteriorating fundamentals announced outside the 48-hour window.

SIF

SIFCO Industries IncIndustrials

$21.64−$6.45

-23.0%

NYSE · Mkt cap $130 M

SIFCO reported third quarter and first nine months fiscal 2026 results on August 10, likely disappointing the market enough to trigger a -22.96% single-day decline, though the headline does not disclose specific financial metrics or guidance changes.

The company announced earnings results for its third quarter and nine-month period ended June 30, 2026 on the same day as the sharp selloff. However, the provided headline does not include actual financial figures, year-over-year comparisons, earnings per share, revenue trends, margin changes, or forward guidance that would explain investor reaction. A 23% single-day drop typically signals material disappointment—either missed earnings expectations, negative guidance, margin compression, or operational issues revealed in the full earnings release. Industrial suppliers like SIFCO are sensitive to demand signals and margin pressures. Without access to the full earnings text, we cannot confirm whether results fell short of consensus, guidance was slashed, or whether the stock had been overbought ahead of the announcement. The timing alignment is clear; the specific catalyst is not disclosed in the headline summary.

CIGL

Concorde International Group Ltd Class A Ordinary SharesIndustrials

$0.46−$0.12

-20.7%

NASDAQ · Mkt cap $100 M

No news headlines were found in the last 48 hours to explain CIGL's 20.70% drop on August 10, 2026. The cause remains unknown without additional information.

The absence of any recent news headlines makes it impossible to identify a specific catalyst for the sharp 20.70% decline. CIGL is a small-cap stock trading at $0.46, which typically characterizes microcap or penny stocks. These securities are prone to large intraday moves driven by several common factors: thin liquidity and low trading volume that amplify price swings, short-selling pressure or forced liquidations, delayed regulatory filings or compliance issues that surface during market hours, retail trading patterns and social media-driven volatility, or simply technical breakdown of support levels. Without access to intraday news, SEC filings, or company announcements released during the trading day, any attribution would be speculation. The stock's low price point suggests it may be subject to heightened volatility independent of fundamental catalysts.

GCTS

GCT Semiconductor Holding, Inc.Technology

$2.47−$0.52

-20.3%

NYSE · Mkt cap $182 M

GCT Semiconductor reported Q2 2026 results and a business update on August 10, likely containing disappointing guidance, revenue miss, or margin compression that triggered a sharp 20% sell-off among the day's biggest losers.

The only headline available is GCT Semiconductor's earnings release and business update published the same day as the 20% drop, making it the most probable catalyst. Semiconductor companies typically trade on forward guidance, gross margins, and demand signals more than trailing earnings. Without access to the actual financial results or guidance revision within the earnings release, I cannot identify the specific miss—whether revenue fell short of consensus, management lowered Q3/full-year guidance, gross margins compressed, or the company disclosed a major customer loss or inventory correction. Semiconductor stocks, particularly smaller-cap foundries like GCT, are sensitive to utilization rates and leading-edge design wins. The 20% magnitude suggests material negative surprise rather than modest disappointment.

BTDR

Bitdeer Technologies Group - Ordinary SharesTechnology

$8.70−$2.19

-20.1%

NASDAQ · Mkt cap $2.6 B

Bitdeer reported Q2 earnings and revenue that missed Wall Street expectations despite 47% revenue growth, triggering a sharp 20% sell-off as investors repriced the stock following the disappointing earnings surprise and widened net losses.

Bitdeer released Q2 2026 earnings on August 10 that produced mixed results. While the company achieved 47% year-over-year revenue growth to $228.8 million and signed a landmark 16-year AI infrastructure lease with Volta, the headline earnings numbers fell short of Wall Street estimates by 5.71%, and the company reported a widened net loss despite improved adjusted EBITDA of $31.1 million. The massive $266 million in quarterly capital expenditures and ongoing margin pressure appear to have disappointed investors who may have expected profitability to accompany the strong revenue growth. Early pre-market gains of 1.65% reversed sharply during regular trading, suggesting the market initially overlooked the earnings miss but repriced downward as the full earnings call details and forward guidance became available. The 20% drop ranks this as the 21st biggest loser of the day, indicating sector-wide or broader market headwinds may have amplified the sell-off.

VIVS

Organovo Holdings, Inc.Healthcare

$0.36−$0.09

-20.1%

NASDAQ · Mkt cap $1.1 M

No news headlines were found in the last 48 hours to explain Organovo's 20% drop on August 10, 2026. The decline likely stems from technical selling, sector headwinds, or delayed news that has not yet been indexed.

Yahoo Finance returned no recent headlines for VIVS in the 48-hour window preceding this significant move. This creates a genuine data gap. Organovo is a biotech firm focused on 3D tissue engineering and organ models, sectors historically sensitive to cash burn concerns, regulatory setbacks, funding announcements, partnership deals, or clinical trial results. Without a specific catalyst in the headlines, the move could reflect several scenarios: (1) technical selling following prior gains or weakness in the broader biotech index, (2) a delayed or embargoed announcement not yet picked up by the RSS feed, (3) insider or institutional selling tied to known upcoming milestones, or (4) market reaction to competitive or industry news unrelated to VIVS directly. The rank as 22 biggest loser suggests this is a real market move, not data error, but its origin remains unclear from available headline data.

NOTE

FiscalNote Holdings, Inc.Technology

$0.08−$0.02

-20.1%

NYSE · Mkt cap $2.0 M

No relevant news headlines were found in the last 48 hours, so the 20% drop on August 10 likely reflects either a delayed market reaction to a prior announcement, technical selling, or undisclosed company-specific developments not yet captured in major news feeds.

FiscalNote Holdings dropped 20% to $0.08 on August 10, 2026, yet no recent news headlines appear in the available feed. This disconnect between a significant price move and absent headlines suggests several possibilities. First, the catalyst may predate the 48-hour window and the market is continuing to price it in. Second, the stock may be experiencing technical momentum or algorithmic selling, particularly common in lower-priced equities with thin liquidity. Third, a material announcement or disclosure may exist but has not yet been indexed by Yahoo Finance's RSS feed, or the company may have released information via SEC filing, investor call, or other channels not yet reflected in headline aggregators. For a company in the government relations and regulatory intelligence space like FiscalNote, moves can also reflect broader sector weakness or changes in client demand. Without substantive news evidence, pinpointing the precise cause is not possible.

RETO

Reto Eco-solutions IncBasic Materials

$2.43−$0.61

-20.1%

NASDAQ · Mkt cap $13 M

No news headlines appeared in the last 48 hours, so the 20% drop cannot be directly attributed to a reported event. The decline likely reflects either a delayed market reaction to older news, technical selling pressure, or untracked company-specific developments.

The absence of recent headlines makes it impossible to identify a specific catalyst for RETO's sharp 20% intraday decline. Eco-solutions companies can be sensitive to shifts in environmental policy, commodity prices, regulatory changes, or quarterly performance surprises, but none of these appear in the available news feed. The stock's rank as the 24th biggest loser suggests this was a material move affecting the broader market or reflecting a company-specific shock. Possible causes include a delayed reaction to earnings results released more than 48 hours ago, an untracked earnings warning or insider event, technical support breakdown, or short-covering reversals common in lower-capitalization stocks. Without corroborating news, we cannot distinguish between these scenarios.

VIP

Vulcan Infrastructure and Power Inc.Financial Services

$1.65−$0.41

-19.8%

NASDAQ · Mkt cap $34 M

VIP dropped 19.76% with no news headlines in the last 48 hours, making the precise trigger unclear; the move likely reflects a negative catalyst such as an earnings miss, guidance cut, or material company announcement that has not yet appeared in the captured news feeds.

The absence of recent news headlines is notable given the magnitude of the decline. A nearly 20 percent single-day loss for a stock typically correlates with a material negative event: earnings disappointment, downward guidance revision, loss of a major contract, insider selling disclosure, analyst downgrade, or sector-wide selloff. For an infrastructure and power company like VIP, catalysts could include revised project timelines, regulatory setbacks, financing challenges, or macro headwinds affecting utilities and energy sectors. It is also possible that news was released but has not yet propagated to the Yahoo Finance RSS feed captured in this snapshot, or that the stock reacted to after-hours developments or broader market conditions not individually attributed to company-specific news.

TCX

Tucows IncTechnology

$12.77−$2.98

-18.9%

NASDAQ · Mkt cap $114 M

No news headlines were found in the last 48 hours for TCX, so the 18.92% decline cannot be directly attributed to a reported catalyst. The drop likely reflects broad market conditions, technical selling, or unannounced company developments.

Yahoo Finance returned no headlines for Tucows in the past two days, which means we cannot point to a specific earnings miss, guidance cut, partnership loss, or other discrete event as the documented cause of this significant drop. Tucows operates in the domain registry and web hosting space, sectors that can be sensitive to changes in internet infrastructure costs, customer churn, or competitive pressure. Without news, the decline could reflect several categories of cause: technical selling pressure following a prior run-up, sector-wide weakness in the hosting or registry business, an analyst downgrade or internal warning not yet captured in headlines, or delayed disclosure of negative developments. It is also possible the move reflects intraday volatility or a data anomaly, though an 18.92% single-day loss is material enough to suggest genuine selling interest.

ENSC

Ensysce Biosciences, Inc.Healthcare

$0.43−$0.10

-18.7%

NASDAQ · Mkt cap $7.5 M

No news headlines were found in the last 48 hours, so the cause of the 18.68% drop cannot be directly attributed to a public announcement. The decline may reflect sector weakness, technical selling, or undisclosed developments.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for ENSC's sharp 18.68% decline on August 10, 2026. For a small-cap biotech company like Ensysce, which develops abuse-deterrent opioid formulations, typical drivers of large single-day moves include clinical trial results, regulatory setbacks or approvals from the FDA, partnership announcements, capital raises, or guidance revisions. The stock's low price of $0.43 and ranking as the 27th biggest loser suggest moderate trading volume and heightened volatility typical of micro-cap equities. Without headline evidence, the drop could reflect broader biotech sector pressure, profit-taking after a prior rally, a delayed announcement that has not yet surfaced in the RSS feed, or technical momentum selling in a thinly traded name.

WWR

Westwater Resources IncBasic Materials

$0.62−$0.14

-18.1%

NYSE · Mkt cap $73 M

Westwater announced EXIM approval for a $25 million loan to advance its Kellyton graphite plant on the same day the stock fell 18%, suggesting the market may have interpreted the news as insufficient, dilutive, or disappointing relative to expectations.

The headline confirms that Westwater secured export financing approval for a major project, which would normally be viewed as positive. However, the stock declined sharply on the announcement day, indicating the market's reaction was negative. This disconnect suggests several possibilities: the $25 million funding amount may be seen as inadequate for the project's full capital requirements, implying future dilution or financing challenges; the terms or conditions of the loan may be unfavorable; or the market had expected a larger funding package or better news. Without additional context on the company's prior guidance, cash position, or analyst expectations, we cannot definitively determine whether this represents a genuine disappointment or a reversal of inflated pre-announcement sentiment. Graphite and battery materials companies are capital-intensive and have faced market skepticism about project execution timelines and demand.

SSM

Sono Group N.V.Consumer Cyclical

$3.04−$0.65

-18.1%

NASDAQ · Mkt cap $3.8 M

No news headlines were found in the last 48 hours to explain Sono Group's 18.11% decline on August 10, 2026. The drop likely reflects either negative developments not yet captured in available news, technical selling pressure, or broader market headwinds affecting the solar vehicle sector.

The absence of any news headlines in the last 48 hours makes direct causation impossible to establish. Sono Group is a solar electric vehicle company that has faced significant market skepticism historically regarding commercialization timelines and capital requirements. For a stock down 18 percent on a day ranked among the 29 largest losers, the catalyst typically falls into one of several categories: delayed or cancelled product milestones, capital raise dilution announcements, competitive setbacks, or broad sector rotation away from speculative cleantech names. Without headline evidence, we cannot distinguish between these. It is also possible the move reflects a delayed market reaction to news that has not yet been indexed in the RSS feed provided, or a technical breakdown in a name with thin trading liquidity that sometimes experiences outsized moves on low volume.

MEDS

Trxade Group IncHealthcare

$1.61−$0.35

-17.9%

NASDAQ · Mkt cap $4.4 M

No news was found in the last 48 hours to directly explain the 17.86% drop in MEDS stock. The decline likely stems from sector-wide pressure, technical selling, or undisclosed company developments not yet captured in headlines.

The absence of recent news headlines for MEDS creates a factual gap in understanding the cause of this significant single-day loss. Trxade Group is a small-cap healthcare distributor operating in a sector sensitive to regulatory changes, competitive pressure, and macroeconomic conditions. Without news, the drop could reflect several possibilities: technical breakdown at support levels, investor rotation out of micro-cap healthcare plays, negative commentary from an analyst not yet syndicated to major feeds, or internal company news that has not yet propagated to public sources. Small-cap stocks often exhibit heightened intraday volatility unmoored from news flow, making them susceptible to momentum selling and redemptions. Without concrete information, any specific catalyst remains speculative.

CEVA

CEVA IncTechnology

$31.88−$6.82

-17.6%

NASDAQ · Mkt cap $744 M

CEVA beat Q2 earnings and revenue estimates with record licensing growth and raised 2026 guidance, yet the stock fell 17.61%, suggesting a "sell the news" reaction where strong results were already priced in or guidance/outlook disappointed relative to market expectations.

The headline evidence establishes that CEVA delivered measurable outperformance on 2026 Q2 results: 13% revenue growth, earnings surprise of +14.29%, revenue surprise of +3.08%, and the company raised full-year 2026 guidance. Multiple sources confirm the earnings beat and note record-level licensing performance, which is strategically significant for an IP licensing business. However, the stock fell sharply despite this positive data, which is a classic "sell the news" or "miss the whisper number" pattern. One of the headlines explicitly notes "Ceva stock fell" despite topping targets, suggesting the market's expectations diverged from reported performance. Without access to the actual guidance raise magnitude, forward margin outlook, or management commentary on near-term AI demand, it is reasonable to infer that either (a) guidance did not exceed consensus expectations sufficiently, (b) management commentary signaled caution for future quarters, or (c) prior rumors had already embedded these results into the price. The 17.61% drop is severe enough to suggest something beyond gentle disappointment.

SLXN

Biomotion SciencesHealthcare

$1.53−$0.32

-17.3%

NASDAQ · Mkt cap $540 K

No news headlines were found in the last 48 hours, so the 17.34% decline cannot be attributed to a specific announced event. The drop likely reflects either a delayed market reaction to prior news, technical selling, or sector-wide pressure in biotech.

The absence of recent news makes it difficult to pinpoint the exact catalyst for SLXN's sharp 17.34% decline. Biomotion Sciences is a small-cap biotech name trading near $1.53, making it susceptible to multiple types of pressure: delayed reactions to clinical trial results or regulatory setbacks announced earlier, liquidity-driven selling in a weak biotech environment, short covering or long liquidation, or sector rotation away from unprofitable development-stage companies. Without access to headlines from the prior week or company filings, identifying the specific trigger requires inference about typical drivers for stocks in this category, particularly clinical-stage biotech names that often trade on sentiment and funding prospects.

ARKO

Arko Corp.Consumer Cyclical

$4.70−$0.95

-16.8%

NASDAQ · Mkt cap $532 M

ARKO fell 16.81% despite raising fuel-margin guidance and keeping EBITDA guidance intact, suggesting market concern about softening retail demand or deal integration risks outweighed the positive operational updates.

The headlines reveal that ARKO announced the USPP acquisition (adding 400 wholesale locations) and held an earnings call where management raised fuel-margin outlook while maintaining 2026 EBITDA guidance. On the surface these are constructive developments: margin expansion, an accretive wholesale network addition, and confidence in full-year targets. However, the same earnings commentary explicitly acknowledges softer retail demand, which appears to have triggered the sharp sell-off. The market may be interpreting the softer retail environment as a structural headwind that outweighs near-term margin gains and wholesale expansion. Additionally, integration risks or skepticism about achieving the promised synergies from the USPP deal could be driving concern. The magnitude of the decline suggests something more than routine quarterly pressure, but without additional reporting on valuation context, guidance specifics, or analyst commentary, we cannot definitively isolate whether the sell-off stems from demand concerns, deal execution risk, or a combination of both.

AXTI

AXT IncTechnology

$73.81−$14.70

-16.6%

NASDAQ · Mkt cap $3.7 B

No news headlines were found in the last 48 hours, so the 16.61% drop on August 10, 2026 cannot be directly attributed to a disclosed catalyst. The decline likely reflects either a delayed market reaction to an earlier event, technical selling, or undisclosed developments.

AXT Inc, a semiconductor equipment manufacturer, experienced a substantial single-day loss with no corresponding news coverage in the recent news feed. This disconnect suggests either the triggering event occurred earlier than the 48-hour window captured, or the market moved on private information, technical factors, or sector-wide weakness not represented in the available headlines. Semiconductor equipment stocks are sensitive to cyclical demand, capital spending revisions, margin concerns, and competitive pressures. Without access to earnings dates, guidance changes, competitive announcements, or supply chain disruptions from the provided sources, we cannot pinpoint the specific catalyst. This type of stock typically reacts to quarterly results, major customer orders or cancellations, manufacturing delays, or macroeconomic shifts affecting semiconductor capex budgets.

WLDS

Wearable Devices LtdTechnology

$3.50−$0.68

-16.3%

NASDAQ · Mkt cap $6.0 M

No news headlines were found in the last 48 hours for WLDS, so the 16.27% drop likely stems from technical selling, sector weakness, or an unannounced catalyst not yet picked up by major financial news sources.

The absence of any recent news headlines makes it impossible to attribute the significant 16.27% decline to a specific company announcement or event. For a small-cap wearable devices company, common catalysts for sharp downward moves typically include disappointing earnings or guidance, product delays, cash burn concerns, competitive threats, or sector rotation out of consumer electronics and IoT stocks. Wearable device makers are also sensitive to broader technology spending pullbacks and consumer discretionary weakness. Without accompanying news coverage, the drop could also reflect technical selling pressure after a previous run-up, options expiration effects, or circulation of non-public information prior to an official announcement. The rank as the 35th biggest loser suggests moderate market-wide participation in the decline, which might point to sector-level weakness rather than company-specific bad news.

TLS

Telos CorpTechnology

$4.03−$0.77

-16.0%

NASDAQ · Mkt cap $331 M

Telos beat Q2 earnings and revenue estimates while raising full-year guidance, yet the stock fell 15.95%, suggesting a sell-the-news reaction or market disappointment relative to forward expectations despite the strong absolute results.

The headline evidence is paradoxical. Telos reported second-quarter 2026 revenue and adjusted EBITDA above guidance, with 33% revenue growth, earnings surprise of +100%, and a raised full-year adjusted EBITDA outlook. Typically such results drive gains, not a near-16% drop. The most likely explanations are: first, a sell-the-news dynamic where the strong quarter was already priced in and investors took profits; second, the company's forward guidance or management commentary may have disappointed despite the beat, suggesting deceleration ahead or margin pressures not evident in the headline summaries; third, the market may have expected even larger upside given the magnitude of the revenue beat. Without the full earnings transcript or guidance details, the precise cause of the sell-off cannot be determined from these headlines alone, but the disconnect between strong results and sharp declines often points to guidance or commentary that tempered enthusiasm.

UCAR

U Power Limited - Ordinary SharesConsumer Cyclical

$0.73−$0.14

-15.7%

NASDAQ · Mkt cap $15 M

No news was found in the last 48 hours to explain the 15.73% drop in UCAR stock, so the decline likely resulted from technical selling, sector weakness, or undisclosed company developments.

The absence of any headlines in Yahoo Finance's RSS feed over the past 48 hours makes it difficult to pinpoint a specific catalyst for this sharp 15.73% decline. U Power Limited is a relatively low-priced stock trading at $0.73, which can exhibit high volatility and sensitivity to thin trading volumes, insider activity, or negative sentiment that may not be immediately documented in major news outlets. The most plausible categories of cause are: first, broad market or sector-specific weakness affecting small-cap or energy-related equities; second, a technical breakdown or forced selling from margin calls or systematic hedge fund rebalancing; or third, an announcement or development that has not yet been indexed by major financial news services. Without specific headlines to analyze, we cannot distinguish between these possibilities.

LTCH

Latch, Inc.Technology

$0.16−$0.03

-15.4%

NASDAQ · Mkt cap $31 M

No news headlines were reported in the last 48 hours for LTCH, so the 15.43% single-day drop cannot be tied to a specific announced catalyst. The decline likely reflects broad market sentiment, technical selling, or unannounced developments.

The absence of recent news headlines makes it impossible to identify a concrete reason for today's 15.43% loss. Latch is a micro-cap security trading at $0.16, which is characteristic of highly volatile, illiquid stocks that can experience sharp daily moves on modest volume or sentiment shifts. Possible drivers could include technical breakdown below a support level, liquidation pressure from existing shareholders, delayed or negative quarterly results not yet widely reported, or sector-wide pressure in smart-lock or proptech spaces. Without access to intraday trading data, social media sentiment, or institutional flow, attribution remains speculative. The very low price point also suggests the stock may be under pressure from broader fundamental challenges, dilution, or declining market confidence that have accumulated over time.

BHST

BioHarvest Sciences Inc. Common StockConsumer Defensive

$2.10−$0.38

-15.3%

NASDAQ · Mkt cap $46 M

No news headlines were found in the last 48 hours, so the 15.32% drop on BHST cannot be directly attributed to a disclosed catalyst; the decline likely stems from technical selling, broader biotech weakness, or undisclosed company developments.

BioHarvest Sciences is a small-cap biotech firm, and the absence of any news in the RSS feed in the 48 hours preceding this significant 15% drop makes it difficult to pinpoint a specific catalyst. Small-cap biotechs are prone to sharp intraday moves driven by technical factors such as stop-loss cascades, changes in short interest, or sector-wide weakness in growth-stage life science stocks. Alternatively, the decline could reflect a delayed market reaction to earlier news that has not yet appeared in the RSS feed, or an internal corporate development such as a capital raise announcement, clinical setback, or insider transaction disclosed through SEC filing rather than press release. Without access to real-time SEC filings or company announcements, the cause remains speculative.

IPCXR

Inflection Point Acquisition Corp. III Rights

$0.32−$0.06

-15.1%

NASDAQ

No news headlines were found in the last 48 hours, so the 15% decline in IPCXR cannot be attributed to a specific announced event. For a SPAC rights unit, price pressure typically stems from underlying deal uncertainty or dilution concerns.

Inflection Point Acquisition Corp. III Rights (IPCXR) dropped 15% on August 10, 2026, but no news headlines from the preceding 48 hours are available to explain the move directly. IPCXR is a rights offering tied to a blank-check acquisition vehicle, making it sensitive to investor sentiment about the sponsor's ability to complete a merger at attractive terms. Declines in SPAC-related securities can be driven by several structural factors: loss of confidence in the deal pipeline, broader market pullback in SPACs, execution delays on announced acquisitions, or technical selling ahead of rights expiration or conversion deadlines. Without specific news, the decline likely reflects either a wider shift in SPAC sentiment that day or some development regarding the parent company that has not yet been prominently reported in the RSS feeds tracked.

CEPL

Capstone Energy Plus, Inc.Industrials

$7.32−$1.24

-14.5%

NASDAQ · Mkt cap $204 M

CEPL fell 14.49% on August 10, 2026, but no news headlines were published in the prior 48 hours, so the specific catalyst cannot be identified from available information.

The absence of news in the last 48 hours means this move cannot be attributed to a company announcement, earnings release, regulatory action, or other disclosed event. For a small-cap energy stock like Capstone Energy Plus, a 14% single-day drop without headline support could reflect several categories of catalyst: delayed news from before the snapshot window, intraday rumors or social media activity, broad sector rotation out of energy names, technical selling from broken support levels, short covering unwinding, or idiosyncratic liquidity events. Energy stocks are also cyclically sensitive to crude oil price movements and macroeconomic sentiment, either of which could drive a sharp move without company-specific news. Without access to intraday market data, trading volume, or sector performance context, the true driver remains unclear.

CVM

CEL-SCI CorpHealthcare

$1.47−$0.25

-14.5%

HCWC

Healthy Choice Wellness Corp.Consumer Defensive

$0.26−$0.04

-14.5%

NYSE · Mkt cap $7.4 M

No news headlines were published in the last 48 hours for HCWC, so the 14.47% decline cannot be directly attributed to a specific announced event. The drop likely stems from technical selling, sector weakness, or undisclosed developments.

The absence of recent news headlines for HCWC makes it impossible to pinpoint a concrete cause for the 14.47% single-day decline. For a micro-cap wellness stock trading at $0.26, typical catalysts that drive such moves include dilutive equity offerings, insider selling disclosures, delayed regulatory approvals, clinical trial setbacks, or simply thin liquidity amplifying algorithmic or momentum-driven selling. Without access to SEC filings, proprietary news wires, or real-time social media signals, we cannot determine which category applies here. The lack of headline coverage itself may suggest the news, if material, has not yet reached mainstream financial media outlets or was released after market close on August 9th.

MERC

Mercer International IncBasic Materials

$0.51−$0.09

-14.4%

NASDAQ · Mkt cap $31 M

No news headlines were available in the last 48 hours, so the 14.35% decline cannot be directly attributed to a specific announced event or earnings miss. The drop likely reflects broader market conditions, technical selling, or undisclosed company developments.

The absence of recent news headlines makes it difficult to pinpoint a definitive cause for MERC's sharp 14.35% decline on August 10, 2026. Mercer International is a pulp and specialty cellulose manufacturer, a cyclical business sensitive to commodity prices, currency movements, and global demand for forest products. Without reported earnings releases, guidance changes, debt covenant issues, or operational announcements in the last 48 hours, potential explanations include: (1) a market-wide pullback in commodity or forestry-linked equities driven by macroeconomic concerns or weakness in end-market demand; (2) technical breakdown triggered by the stock trading below a key support level; or (3) a material company announcement or analyst downgrade that has not yet been reflected in available Yahoo Finance RSS feeds. The magnitude of the decline suggests a meaningful catalyst rather than random noise, but the nature of that catalyst cannot be confirmed from the provided information.

COHR

Coherent IncTechnology

$325.18−$53.76

-14.2%

NYSE · Mkt cap $57 B

Coherent tumbled 14% as investors took profits after a sharp rally and ahead of upcoming earnings, with growing concern that the AI optics trade has run too far too fast despite strong fundamentals.

The headlines establish that COHR fell sharply on August 10th alongside other optical stocks like Lumentum. The proximate cause appears to be profit-taking and valuation reset rather than negative news: multiple sources note that optical stocks had posted triple-digit gains this year and that the weekend social media debate about optics replacing memory as the hottest AI trade drove initial Monday optimism, then reversed within minutes. One headline explicitly states the selloff has less to do with bad news than with investors bracing for earnings week. A portfolio analyst called the stock a Hold despite strong AI demand and capacity expansion, citing sharp rally and premium valuation as concerns. This suggests the market repriced risk upward on momentum exhaustion rather than deteriorating fundamentals, though actual earnings results this week could still disappoint.

HELP

Cybin Inc.Healthcare

$10.00−$1.61

-13.8%

NASDAQ · Mkt cap $730 M

Cybin announced a new CEO (Michael Halstead, effective August 3) and is participating in a pharma conference on August 12; the stock fell 13.84% today, likely reflecting investor skepticism about leadership change or broader sector weakness unrelated to the news.

The two headlines are both positive in framing: a new CEO with 25 years of pharma experience and a conference appearance. Neither announces negative clinical data, failed trials, guidance cuts, or capital raises that would mechanically trigger a sell-off. The CEO appointment occurred on August 3, yet the stock dropped sharply on August 10—a one-week lag that suggests the market may have been digesting the leadership change over time, or that today's decline stems from an unrelated factor such as sector rotation, broader biotech weakness, or a delayed market reaction to something not captured in these headlines. Without access to intraday news, trading volumes, short interest data, or the broader market context for small-cap biotech on August 10, 2026, the true catalyst remains unclear.

HCICR

Hennessy Capital Investment Corp. VIII Share Rights

$0.15−$0.02

-13.7%

NASDAQ

No news headlines were found in the last 48 hours, so the 13.68% decline cannot be tied to a specific catalyst. For a blank-check company rights offering like HCICR, typical drivers of intraday declines include technical de-listing pressure, changes in redemption expectations, or broader SPAC sen…

Hennessy Capital Investment Corp. VIII Share Rights (HCICR) is a SPAC-related security representing redemption rights tied to a special purpose acquisition vehicle. The lack of news in the last 48 hours means we cannot attribute this decline to earnings, a merger announcement, or company-specific developments. Rights offerings and SPAC instruments are sensitive to several factors: shifts in the underlying SPAC's merger timeline or valuation, changes in shareholder redemption sentiment, broader market appetite for SPAC-related vehicles, or technical trading patterns among arbitrage desks and retail traders. The 13.68% drop is notable but not unusual for low-priced, thinly traded rights that can experience volatile swings on modest volume. Without concurrent news, the most likely causes are technical factors, redemption flow changes, or delayed reactions to earlier announcements now surfacing in pricing.

BRCC

BRC Inc.Consumer Defensive

$0.86−$0.14

-13.6%

NYSE · Mkt cap $203 M

BRC Inc. announced a 1-for-10 reverse stock split on August 10, which typically signals financial distress and dilution concerns, likely driving the 13.59% same-day decline despite the mechanical price adjustment.

The company announced a reverse stock split effective today. Reverse splits are mechanically neutral on market capitalization but are widely perceived as a negative signal by markets because they are typically used by struggling companies to maintain exchange listing compliance or improve optics after sustained declines. While the headline is truncated and does not provide the full rationale, the timing of the announcement with the same-day 13.59% drop suggests investor concern about the company's financial trajectory or dilution risk. For a premium coffee company like Black Rifle Coffee, fundamental questions about profitability, competitive positioning, or execution may underlie the need for such a move. Without details on the company's recent earnings, guidance, or balance sheet, the exact trigger remains partially unclear, but the reverse split announcement itself is the most credible catalyst for the negative price action.

APYX

Apyx Medical CorpHealthcare

$3.47−$0.54

-13.5%

NASDAQ · Mkt cap $133 M

No news headlines are available in the last 48 hours to explain the 13.47% drop in APYX stock, so the cause remains unclear without additional information about company announcements or market events.

The absence of any news headlines in the last 48 hours makes it difficult to pinpoint a specific catalyst for the sharp 13.47% decline. For a small-cap medical device company like Apyx Medical, typical drivers of sudden losses include clinical trial setbacks, regulatory delays or rejections, disappointing quarterly results, guidance cuts, or negative commentary from analysts or institutional investors. The stock's ranking as the 49th biggest loser suggests this was a meaningful market-wide move on August 10, 2026, but without accompanying news coverage it is equally possible the decline reflects delayed disclosure of an event, technical selling pressure, or information spreading through channels not captured in the headline feed. Without concrete evidence of a specific corporate action or announcement, any explanation remains speculative.

SOAR

Volato Group, Inc.Industrials

$0.17−$0.03

-13.4%

NYSE · Mkt cap $7.8 M

No news headlines were found in the last 48 hours covering SOAR, so the 13.42% decline cannot be directly attributed to a specific announced catalyst. The drop likely reflects either technical selling pressure, sector headwinds in aviation services, or undisclosed company developments.

The absence of recent headlines makes it impossible to tie today's sharp decline to a discrete news event like earnings, guidance, or operational announcements. Volato Group is a fractional aircraft ownership and management company operating in a niche, capital-intensive market segment. Stocks in this category can experience significant intraday moves on thin trading volume, lack of analyst coverage, or broad-based sell-offs in aviation and luxury services sectors. It is also possible that news broke outside the Yahoo Finance RSS feed capture window, or that the move reflects accumulated negative sentiment from earlier announcements. Without visibility into trading volume, insider activity, or sector-level movements on this date, attribution remains speculative.